AlphAIAlphAI — Financial news for AI agents
investing.comOCT 281 min read$SLS

Sellas Life Sciences phase 3 AML trial reaches key milestone

SELLAS Life Sciences (NASDAQ:SLS) announced its Phase 3 REGAL trial for galinpepimut-S in AML patients reached the 80th event, triggering final analysis. The company plans to release topline results this quarter. Galinpepimut-S targets the WT1 protein and is being evaluated for maintenance therapy in AML. SELLAS also develops SLS009, a CDK9 inhibitor for AML.

Original reporting
investing.com
Published Oct 28, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SLS
Neutral
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SLSNeutralMed
01

Why it matters

The 80th event triggers data lock and unblinding, setting the stage for a market‑moving data release later this quarter.

02

Market read

First report of a pivotal trial milestone; potential catalyst for SLS and related oncology stocks.

03

What to watch

Regulatory review timelines and competition from other WT1‑targeted therapies could temper upside.

Relevance 9/10Novelty 9/10Timing: preliminary topline results expected this quarter

Background

Sellas Life Sciences (NASDAQ:SLS) is a late‑stage biopharma focused on cancer therapies, with its REGAL trial evaluating galinpepimut‑S as maintenance for AML patients in second remission.

Company-level read

Ticker impact

$SLSNeutralHigh confidence
Context

Sellas Life Sciences announced its Phase 3 REGAL trial hit the pre‑specified 80th death event, triggering final analysis and upcoming topline results.

Expected impact

potential upside as investors price in positive trial outcomes

Evidence & confidence

First disclosure of a pivotal trial event; market typically reacts strongly to early‑stage data releases.

Market effects

Sector

Positive data could boost the broader oncology biotech sector.

Regional

Limited to U.S. biotech investors; no immediate regional effect.

Global

May influence global AML therapeutic pipelines and related biotech stocks.

Counterpoint

What could challenge this read

If the trial fails to meet survival endpoints, the stock could sharply decline.

Key entities

  • company
    Sellas Life Sciences Group, Inc.

    US‑listed biotech developing galinpepimut‑S and CDK9 inhibitor SLS009.

  • institution
    Memorial Sloan Kettering Cancer Center

    Licensor of galinpepimut‑S.

Read at source← All news

StorySELLAS Life Sciences reaches 80th death in Phase 3 AML trial, triggering final analysis

Related articles

SEP 24
$SLSMedAI 8/10

SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY

Sellas Life Sciences (SLS) stock rose 2% to $13.76 after updating its SLS009 trial for AML, which includes drugs from AbbVie (ABBV), Roche (RHHBY), and Bristol Myers Squibb (BMY). The trial, in early-to-mid stages, tests SLS009 alone and in combination. SLS focuses on its Phase 3 Regal trial, nearing final analysis. CEO Angelos Stergiou addressed criticism, emphasizing data over noise. Retail sentiment remains bullish.

stocktwits.com2 min
SEP 5
$SLSMed

Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential

Sellas Life Sciences (SLS) shares rose 5.4% after Alliance Global analyst James Molloy highlighted the potential of its experimental drug SLS009 for treating acute myeloid leukemia. Molloy raised the price target to $35, suggesting 200% upside. SLS009 is in a Phase 2 trial with topline data expected in Q4 2026. Sellas reported a Q2 net loss of $9.6 million, wider than estimates, with R&D costs increasing. Cash reserves totaled $138.3 million.

stocktwits.com2 min